APLN and oligodendroglioma: The high APLN expression had poor OS in LGG patients with seizure history (p = 4E − 04; HR: 2.3864; 95% CI: 1.4689-3.877; Figure 3(a)), with primary tumor (p < 0.0001; HR: 2.1598; 95% CI: 1.4796-3.1526; Figure 3(b)), with targeted molecular therapy (p = 3.59E − 2; HR: 1.6976; 95% CI: 1.0355-2.7829; Figure 3(c)), without targeted molecular therapy (p = 2.7E − 3; HR: 2.6399; 95% CI: 1.3985-4.9834; Figure 3(d)), and with oligodendroglioma (p = 9E − 04; HR: 2.9098; 95% CI: 1.5501-5.4622; Figure 3(e)).